Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.71 |
| ▸ | ANPEP | P15144 | 4/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19744399 | 0.87 | MMP2 (0.54) | MMP2ANPEPATMDPP7DPP8 | |
| SCHEMBL21682451 | 0.87 | MMP2 (0.54) | MMP2ANPEPATMDPP7DPP8 | |
| SCHEMBL29260191 | 0.87 | MMP2 (0.54) | MMP2ANPEPATMDPP7DPP8 | |
| SCHEMBL19744398 | 0.87 | MMP2 (0.54) | MMP2ANPEPATMDPP7DPP8 | |
| SCHEMBL18339420 | 0.87 | MMP2 (0.54) | MMP2ANPEPATMDPP7DPP8 | |
| SCHEMBL30476594 | 0.83 | MMP2 (1.00) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL16171927 | 0.83 | MMP2 (1.00) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL23038367 | 0.80 | MMP2 (0.51) | MMP2ANPEPATMDPP7DPP8 | |
| SCHEMBL20705291 | 0.80 | MMP2 (0.51) | MMP2ANPEPATMDPP7DPP8 | |
| SCHEMBL13836866 | 0.80 | MMP2 (0.51) | MMP2ANPEPATMDPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | API5, BIRC5, BAD | MMP2 2035/4885ANPEP 1414/4885ATM 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.